A 2024 RAND study found that US drug prices are 278% higher than in 33 other developed countries in the OECD.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The gaming industry boomed during the pandemic, but its rapid growth didn’t continue once consumers could go outside and touch grass.
BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”
One of the year’s hottest stocks, Oklo, shed a fifth of its value amid an insider selloff, prompting Goldman Sachs to caution investors.
Lame duck Disney CEO Bob Iger will likely have his hands full with pressure from regulators and investors in his remaining days on the job.
Breeze, which was started by JetBlue’s founder, said it’s the first sizable airline since Virgin America to get the global go-ahead.
Like chipmaker Intel and rare earths producer MP Materials, the US sees its investment in Lithium Americas as being in the national interest.
Shares of Plug Power, a hydrogen tech provider, have exploded in the past week, climbing roughly 50% through the past five trading sessions.
In fact, Boeing’s been soaring through somewhat smoother skies ever since the calendar turned over to 2025.
Studies exploring whether there’s a connection between Tylenol’s key ingredient acetaminophen and autism have had mixed results.
Tying its various advertising tech services together has allowed Google to snare roughly 20% of each dollar that moves through its platforms.
And yet, last week, Tesla scored a couple key brownie points from Wall Street analysts. So why the optimism?
Lachlan Murdoch’s moves so far are clearly those of someone who came of age during an era of rapidly advancing digitization.
Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.
Demand for copper, already one of the most commonly used metals in the world, has surged amid the AI computing boom.